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Abstract Introduction Drug-induced QT-prolongation is
an established risk factor for Torsade de pointes and sud-
den cardiac death. The list of QT-prolonging drugs is
extensive and includes many drugs commonly used in
psychiatry. Aim In this study we performed a cross-sec-
tional analysis of medication profiles to assess the preva-
lence of drug interactions potentially leading to QT-
prolongation. Setting 6 psychiatric hospitals in Flanders,
Belgium. Methods For each patient, the full medication list
was screened for the presence of interactions, with special
attention to those with an increased risk for QT-prolonga-
tion. Current practice on QT monitoring and prevention of
drug-induced arrhythmia was assessed. Main outcome
measure Number of drug interactions with risk of QT-
prolongation. Results 592 patients (46 % female; mean age
55.7 ± 17.1 years) were included in the analysis. 113 QT-
prolonging interactions were identified in 43 patients
(7.3 %). QT-prolonging interactions occurred most fre-
quently with antidepressants (n = 102) and antipsychotics
(n = 100). The precautions and follow-up provided by the
different institutions when combining QT-prolonging drugs
were very diverse. Conclusion Drug combinations that are
associated with QT-prolongation are frequently used in the
chronic psychiatric setting. Persistent efforts should be
undertaken to provide caregivers with clear guidelines on
how to use these drugs in a responsible and safe way.
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Impact of findings on practice
• QT-prolonging drugs (especially antidepressants and
antipsychotic medication) are often combined in psy-
chiatry, increasing the risk of QT-prolongation and
Torsades de Pointes. Clear protocols for prescribing
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and follow-up of (combinations of) these drugs are
needed.
• There is a need for increased awareness of the risk of
QT-prolongation among healthcare professionals and
for initiatives to improve the current practice.
Introduction
Worldwide more than 3 million people die annually from
sudden cardiac death (SCD) [1]. In developed countries,
SCD accounts for 20 % of the total mortality [2–4]. Most
of these cases are caused by ventricular arrhythmias (VA)
[e.g. ventricular tachycardia and fibrillation (VT/VF)] [1–
4]. Prolongation of the QT-interval is a known risk factor
for Torsade de Pointes (TdP) with a possible deterioration
in VT/VF leading to SCD [4–7]. Because the QT-interval is
inversely related with heart rate, different correction for-
mulae (e.g. Bazett, Fredericia) have been developed to
calculate a heart rate corrected QT time (QTc) [8].
According to the expert group from the American Heart
Association and the American College of Cardiology
Foundation, a QTc-interval above 470 ms for adult males
and 480 ms for adult females should be considered
abnormal [5]. Patients with a QTc of 500 ms or more are
considered to be at high risk for developing TdP [5, 6].
An important risk factor for developing QT-prolonga-
tion is the use of certain drugs. The list of drugs associated
with QT-prolongation is extensive [9]. Multiple drugs have
been withdrawn from the market or restricted in their use
because of QT-prolonging effects [6, 10, 11]. Drug inter-
actions can further increase TdP risk, either by a pharma-
codynamic (cumulative effect of two QT-prolonging drugs)
or a pharmacokinetic interaction (reducing the metaboli-
zation of a QT-prolonging drug) [12].
The individual susceptibility to QT-prolongation and
arrhythmia depends on multiple risk factors, of which the
most important are baseline QT-prolongation, female sex,
electrolyte disturbances (hypokalemia, hypomagnesaemia),
bradycardia, and hereditary cardiac abnormalities (long QT
syndrome, ion channel polymorphisms) [5, 6].
Psychiatric patients can be considered a population at
risk for drug-induced TdP, because many antipsychotic and
antidepressant agents are associated with QT-prolongation.
A list of antidepressants and antipsychotics associated with
QT-prolongation (in accordance with the AZCERT Clas-
sification [9]) is presented in Table 1. Both typical and
atypical antipsychotics are associated with QT-prolonga-
tion and TdP [13, 14]. Leonard et al. [15] conducted a
retrospective cohort study to compare the VA/SCD risk of
different antipsychotic drugs. The results show that halo-
peridol and chlorpromazine have a higher VA/SCD risk
than olanzapine, risperidone a similar risk and quetiapine a
30 % lower risk than olanzapine. Among antidepressants,
there is more uncertainty. Several case reports have linked
‘selective serotonin reuptake inhibitors’ (SSRI) with QT-
prolongation, but other evidence is limited. Citalopram and
escitalopram appear more likely than others to prolong the
Table 1 AZCERT classification (version December 2013): antipsy-
chotics and antidepressants with risk of QT-prolongation and Torsade
de Pointes [9] (drugs are coded in accordance with the ATC-index of
the WHO [28])
Antipsychotics Antidepressants
List 1: Risk of Torsade de Pointes
Droperidol (N05AD) Citalopram (N06AB)
Haloperidol (N05AD) Escitalopram (N06AB)
Pimozide (N05AG)
Chlorpromazine (N05AA)a
Mesoridazine (N05AA)a
Sulpiride (N05AL)
Thioridazine (N05AA)a
List 2: Possible risk of Torsade de Pointes
Clozapine (N05AH) Lithium (N05AN)
Olanzapine (N05AH)
Paliperidon (N05AX) Mirtazapine (N06AX)
Quetiapine (N05AH) Venlafaxine (N06AX)
Risperidone (N05AX)
Sertindol (N05AE)
Iloperidone (N05AX)a
Ziprasidone (N05AE)a
List 3: Conditional risk of Torsade de Pointes
Amisulpride (N05AL) Amitriptyline (N06AA)
Clomipramine (N06AA)
Desipramine (N06AA)a
Doxepine (N06AA)
Fluoxetine (N06AB)
Imipramine (N06AA)
Nortriptyline (N06AA)
Paroxetine (N06AB)
Protriptyline (N06AA)a
Sertraline (N06AB)
Trazodone (N06AX)
Trimipramine (N06AA)a
Risk of TdP substantial evidence supports the conclusion that these
drugs prolong QT intervals and have a risk of TdP when used as
directed in labeling. Possible risk of TdP substantial evidence sup-
ports the conclusion that these drugs can cause QT-prolongation but
there is insufficient evidence that the drugs, when used as directed in
labeling, have a risk of causing TdP. Conditional risk of TdP sub-
stantial evidence supports the conclusion that these drugs prolong QT
and have a risk of developing TdP but only under certain known
conditions
a Not on the market in Belgium
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QT-interval. Tricyclic antidepressants are also associated
with QT-prolongation, especially amitriptyline [16, 17].
However, a cohort study of Leonard et al. [18] did not
found significant differences in VA/SCD risk between
paroxetine and 11 other antidepressants. Only mirtazapine
had a significant higher risk of VA/SCD than paroxetine,
but the authors suggest that this could be due to con-
founding factors.
The increased risk of QT-prolongation in psychiatric
patients is also due to the use of combinations of psycho-
tropic drugs [19]. In a German study of Seemuller et al.
[20], 45 % of 1,014 depressed inpatients received a
comedication with an antipsychotic drug. Moreover, data
of the German drug surveillance system [Arzneimittelsi-
cherheit in der Psychiatrie (AMSP), 1994–2009] suggest
that the use of comedication is increasing [21]. Data of a
National Audit of Schizophrenia (NAS) in England and
Wales, involving 5,055 schizophrenia outpatients, revealed
that antipsychotic polypharmacy occurred in 15.9 % of the
patients [22]. Combinations of psychotropic drugs can lead
to additive effects on the QT-interval. Sala et al. [23] found
a significant QT-prolongation following the combination of
an antipsychotic with an antidepressant agent, while
monotherapy with the antipsychotic agent did not signifi-
cant prolonged the QT-interval.
Guidelines to help clinicians to deal with the risk of QT-
prolongation are available. In a guideline of 2010, the
American College of Cardiology Foundation and the
American Heart Association [5] recommend an electro-
cardiogram (ECG) before and 8–12 h after the start, after
raising the dose or with an overdose of a QT-prolonging
drug. They speculate that action (changing therapy,
checking for drug interactions, bradycardia or electrolyte
disturbances) is necessary when the QTc-interval is above
500 ms or the delta QTc is above 60 ms. In a consensus
statement of 2005, the Royale College of Psychiatrists in
London [24] also advise an ECG before and during the
therapy with psychotropic drugs, especially with high
doses, parenteral use, psychotropic drugs with a high risk
of TdP and in patients with a history of cardiovascular
disease. The consensus statement of 2002 by the Cardiac
Safety in Schizophrenia Group [25] stated that individual
risk factors for QT-prolongation and TdP should be verified
and when necessary, the patient should be referred to a
cardiologist.
Few studies have investigated the prevalence of QT-
prolongation in psychiatry [26, 27]. In addition, these
studies had no attention for drug interactions with risk of
QT-prolongation. Therefore, there is only limited evidence
on the prevalence of QT-prolonging drug interactions.
Moreover, data is lacking on current practice in handling
drug interactions with risk of QT-prolongation (in psychi-
atry and in general).
Aim of the study
The aim of this study was to analyze the extent to which
antipsychotics and antidepressants with risk of QT-pro-
longation are combined in psychiatry and to assess the
safety measures that are used to follow-up the risk of QT-
prolongation and TdP in this setting.
Ethical approval
The study protocol was approved by the ethics committees
from the University Hospitals Leuven and from the dif-
ferent psychiatric institutions.
Methods
We used a cross-sectional design to answer our research
question. In May 2008, a total of 600 patients were
included from a convenient sample of 6 psychiatric hos-
pitals in Flanders, Belgium (Sint-Jan hospital, Eeklo (201
beds); Sint-Jan-Baptist hospital, Zelzate (250 beds); Zoete
Nood Gods hospital, Lede (191 beds); Sint-Alexius hos-
pital, Grimbergen (171 beds); Sint-Lucia and Sint-Hier-
onymus hospitals, St-Niklaas (respectively 290 and 220
beds). In each hospital, 100 patients were randomly
selected out of all current inpatients stratified by wards
(similar in the six psychiatric institutions). During data-
analysis, 8 patients were excluded because of incomplete
data. An independent Student’s t test was used to compare
the mean age between genders.
Anonymous demographic data were collected. For each
patient, the full medication list (at the time of inclusion)
was screened for the presence of interactions using the
online tool DelphiCare (available through http://delphicare.
apb.be). The DelphiCare drug database is developed by the
Centre for Pharmaceutical Information (CFI) from the
Belgian Pharmaceutical Association. In addition to infor-
mation on formulation, dosage, side-effects, and (contra)
indications of all drugs used in Belgium, this database also
provides detailed information on drug interactions. The
part about drug interactions is based on the ABDATA-
database (ABDATA Pharma-Daten-Service, http://www.
wuv-gmbh.de). DelphiCare was selected for the screening
of interactions, because in Belgium it is often integrated in
medical and pharmaceutical software used for prescribing
and delivering drugs (as was the case in 4 of the 6 par-
ticipating psychiatric institutions), where it can generate
automatic alerts when a drug is added which could possibly
cause interactions.
The drugs involved in the drug interactions with risk of
QT-prolongation identified by DelphiCare (version 2008),
Int J Clin Pharm (2014) 36:757–765 759
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were compared with the AZCERT classification (version
December 2013) [9].
A non-parametric test (Mann–Whitney U test, 5 %
significance level) was used to compare the average num-
ber of drug interactions per patient profile between the
hospitals where DelphiCare was integrated in the medical
and pharmaceutical software and hospitals without a drug
interaction checker integrated in the software.
The drugs and drug classes involved in the QT-pro-
longing interactions were summarized and coded in
accordance with the ATC-index of the World Health
Organization (WHO) [28]. Furthermore the precautions
and follow-up provided by the different institutions were
assessed. To that purpose, five drug interactions were
randomly selected in each participating hospital, involving
23 patients. For these 23 patients, the pharmacists were
asked to fill out a Case Report Form to check for available
safety measures (ECGs, lab results, evaluation of other risk
factors of the patient). There was also a discussion with the
responsible pharmacist and treating physician.
Data analysis was performed using Microsoft Excel,
Graphpad Prism 5 and SPSS 20 for windows. Data are
presented as mean ± SD or median ± interquartile range
(IQR) when appropriate.
Results
Patient characteristics
The medication profiles of 592 patients were included in
the analysis, equally divided among the participating
institutions (see Table 2). There were 273 females (46 %)
(mean age 55.7 ± 17.1 years) and 319 males (54 %)
(mean age 49.5 ± 17.0 years) with an overall mean age of
52.4 ± 17.3 years (significant difference between the
mean age of males and females (p \ 0.001)). The median
duration of hospital stay at the time of data collection was
166 days (IQR 61–526).
Drug interactions
Screening of the medication profiles with DelphiCare identi-
fied a total of 965 interactions in 360 patients (60.8 %), of
which 593 were graded as severe (61.5 %) and 21 as very
severe (2.2 %) in DelphiCare. Table 2 gives an overview of
the number of interactions in each psychiatric institution.
There was no significant difference in the average number of
drug interactions per patient between hospitals where Del-
phiCare was integrated in the software and hospitals without a
drug interaction checker (p = 0.643).
One hundred thirteen of the 965 interactions (11.7 %)
carried a risk for QT-prolongation (classified as severe or
very severe) and were found in 43 patients (7.3 %) of
which 53.5 % were men. The median duration of hospital
stay for these 43 patients was 117 days (IQR 62–521). Of
these patients, 39.5 % resided in an acute care facility
(median hospital stay 72 days, IQR 41–108); the others in a
chronic care facility (median hospital stay 378 days, IQR
93–657).
The drug classes involved in QT-prolonging interactions
are displayed in Fig. 1. QT-prolonging interactions occur-
red most frequently with antidepressants (n = 102,
90.27 % of cases) and antipsychotics (n = 100, 88.50 % of
cases). In Table 3, the antidepressants and antipsychotics
that were most involved in these interactions are listed.
Table 4 shows the different combinations that occurred the
most.
The results of the comparison of the drugs that were
involved in the drug interactions with risk of QT-prolon-
gation identified by DelphiCare with the QT-drug lists of
AZCERT [9], are displayed in Table 5. More than 50 % of
the drugs that were involved in these drug interactions are
classified in list 1 or list 2 of AZCERT. However, 19.9 %
of the drugs were not classified in the QT-drug lists.
Safety measures
The precautions and follow-up provided by the different
institutions when starting a QT-prolonging drug were very
diverse. In 4 of the 6 institutions, a blood analysis and an
ECG were performed systematically on admission. In 1
hospital, an ECG was only performed at the start of a QT-
prolonging drug. In the last hospital, ECG and blood ana-
lysis were rarely performed.
In none of the six institutions, a follow-up ECG was
performed after starting a QT-prolonging drug if the
baseline ECG was normal. In one hospital, ECG registra-
tion was repeated on a yearly basis, regardless of changes
Table 2 Overview of the number of interactions in the different
psychiatric institutions
Total
number
of patients
Number of
patients with
at least one
drug
interaction (%)
Total
number
of drug
interactions
Average
number
of drug
interactions
per patient
Hospital A 88 61 (69.3) 162 1.84
Hospital Ba 96 55 (57.3) 153 1.59
Hospital Ca 92 52 (56.5) 153 1.66
Hospital Da 96 78 (81.3) 234 2.44
Hospital E 121 73 (60.3) 185 1.53
Hospital Fa 99 41 (41.4) 153 1.55
Total 592 360 (60.8) 965 1.63
a DelphiCare is integrated in the medical and pharmaceutical software used for
prescribing and delivering drugs
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in pharmacotherapy. Other risk factors besides electrolyte
disturbances and baseline QT interval (e.g. history of car-
diovascular disease, familial history of SCD, renal func-
tion) were not systematically documented in the patient
files of the participating institutions.
Discussion
Frequent use and combination of QT-prolonging drugs
Only a few studies investigated the prevalence of QT-
prolonging drug use in clinical practice. In 2003, Curtis
et al. [29] (USA) conducted a retrospective cohort study on
the prescription of QT-prolonging drugs using an outpa-
tient prescription claims database (4.8 million patients): 1.1
million patients (22.8 %) filled prescriptions for at least
one QT-prolonging drug and in this population, 9.4 % fil-
led an overlapping prescription for another QT-prolonging
drug or a drug that prolongs the clearance of the first drug.
Our study differs on several points with this analysis.
Firstly, we focused on psychiatric inpatients instead of a
Fig. 1 Drugs involved in the QT-prolonging interactions (drugs are
coded in accordance with the ATC-index of the WHO [28]).
Antipsychotics N05AA = phenothiazines; N05AD = butyrophenon-
es; N05AE = indole derivatives; N05AF = thioxanthenes;
N05AG = difenylpiperidines; N05AH = diazepines, oxazepines,
thiazepines and oxepines; N05AL = benzamides; N05AN = lithium;
N05AX = other antipsychotics. Antidepressants N06AA = Non-
selective monoamine reuptake inhibitors; N06AB = selective sero-
tonin reuptake inhibitors; N06AX = other antidepressants;
N06CA = antidepressants in combination with psycholeptics. Other
drugs N07BC = Drugs used in opioid dependence; C01BD = anti-
arrhythmics, class III; C02AC = imidazoline receptor agonists;
C03BA = Diuretics, sulfonamides; C07AA = non-selective beta
blocking agents; C09BA = ACE inhibitors and diuretics
Table 3 Antipsychotics and antidepressants that were most involved
in drug interactions with risk of QT-prolongation (drugs are coded in
accordance with the ATC-index of the WHO [28])
Antipsychotics (ATC) Number of
cases
Antidepressants (ATC) Number
of cases
Risperidone (N05AX) 15 Venlafaxine (N06AX) 15
Olanzapine (N05AH) 14 Dosulepine (N06AA) 11
Quetiapine (N05AH) 14 Amitriptyline (N06AA) 11
Table 4 Combinations that most occurred in drug interactions with
risk of QT-prolongation
Combinations Number of cases
Antipsychotic–antidepressant 64
Antipsychotic–antipsychotic 14
Antidepressant–antidepressant 13
Antipsychotic–sotalol 5
Antipsychotic–indapamide 3
Antidepressant–indapamide 3
Antidepressant–lithium 2
Antipsychotic–lithium 1
Antidepressant–sotalol 1
Int J Clin Pharm (2014) 36:757–765 761
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general population. Moreover, we only checked for phar-
macodynamic drug interactions with risk of QT-prolonga-
tion and not for pharmacokinetic interactions. In our (high-
risk) population, QT-prolonging drug interactions were
identified in 7.3 % of patients, as compared with 2.2 % in
the study from Curtis et al.
Haueis et al. [30] published a comparable analysis in the
psychiatric population. They developed an interface for
mass analysis of data from the Clinical Decision Support
Software MediQ and applied it to prescriptions from
84,607 psychiatric inpatients, collected in five countries
(Germany (74.8 %), Switzerland (17.9 %), Austria
(6.4 %), Belgium (0.6 %) and Hungary (0.3 %)). The
analysis, partly based on operational classification of drug
interactions (ORCA), revealed 387,922 drug interactions
(0.6 % high-danger and 18.3 % average-danger) in 79 %
of the patients. Antipsychotics (40.3 %) and antidepres-
sants (15.4 %) were most frequently associated with high-
danger interactions. More than half of the high-danger
interactions resulted in an increased risk of QT-prolonga-
tion. There were no results available for the separate
countries, so comparison of our results with the data of
Belgium in the study of Haueis et al. [30] was not possible.
In our study, 965 interactions were identified (61.5 %
severe and 2.2 % very severe) in 60.8 % of patients. All
QT-prolonging drug interactions were classified as severe
or very severe. QT-prolonging interactions occurred most
frequently with antidepressants (90.27 %) and antipsy-
chotics (88.50 %). Overall, fewer patients were affected
than reported by Haueis et al., but there was a higher
number of severe or high-danger drug interactions. These
differences might be explained by the different classifica-
tion systems that were used. Lack of consistency in the
classification and information provided by different drug
interaction sources can lead to uncertainty among health
care professionals on how to handle the interactions, a
problem that was mentioned before in several studies [31–
33].
In our study, we compared the drugs that were involved
in the drug interactions with risk of QT-prolongation
identified by DelphiCare with the QT-drug lists of AZ-
CERT [9]. In 19.9 % of the cases, the drugs involved in
these interactions were not classified in the QT-drug lists of
AZCERT. This can be due to different availability of drugs
in Belgium and in USA.
Current management of QT-prolonging drugs
in clinical practice
We also assessed the precautions and follow-up provided
by the different institutions to prevent QT-prolongation and
VA. The extent of the use of safety measures was very
diverse. None of the six participated psychiatric institutions
systematically performed an ECG after starting a QT-pro-
longing drug in a patient who already took a drug with risk
of QT-prolongation. Other risk factors of the patients
(besides lab results or baseline QT-interval) were not sys-
tematically documented. The lack of systematic risk man-
agement regarding QT-prolongation is in sharp contrast
with the strict risk management strategies that are imple-
mented for e.g. clozapine induced agranulocytosis and for
lithium induced nephropathy. This highlights the urgent
need for clear protocols to manage these drug interactions
in a safe way. The available international guidelines [5, 24,
25] are not implemented in clinical practice and there is no
Belgian guideline.
We did not find a difference in the average number of
drug interactions per patient between hospitals where
Table 5 Comparison of the drugs that were involved in the drug
interactions with risk of QT-prolongation (DI–QT) identified by
DelphiCare (version 2008), with the QT-drug lists of AZCERT
(version December 2013) [9]
Number of
cases (%)
AZCERT
classificationa
Number of
cases (%)
Drugs involved in DI–QT, classified as very severe by DelphiCare
(n = 26)
Antipsychotics 14 (53.8) List 1 1 (7.1)
List 2 9 (64.3)
List 3 2 (14.3)
Not in lists 2 (14.3)
Antidepressants 9 (34.6) List 1 0
List 2 3 (33.3)
List 3 5 (55.6)
Not in lists 1 (11.1)
Other drugs 3 (11.5) List 1 3 (100.0)
List 2 0
List 3 0
Not in lists 0
Drugs involved in DI–QT, classified as severe by DelphiCare
(n = 200)
Antipsychotics 89 (44.5) List 1 7 (7.9)
List 2 50 (56.2)
List 3 9 (10.1)
Not in lists 23 (25.8)
Antidepressants 97 (48.5) List 1 5 (5.2)
List 2 28 (28.9)
List 3 46 (47.4)
Not in lists 18 (18.6)
Other drugs 14 (7.0) List 1 6 (42.9)
List 2 7 (50.0)
List 3 0
Not in lists 1 (7.1)
a List 1 = risk of TdP, list 2 = possible risk of TdP, list 3 = con-
ditional risk of TdP
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DelphiCare was integrated in the medical and pharma-
ceutical and hospitals without a drug interaction checker
integrated in the software. Previous studies have shown
that drug–drug interaction alerts are often overruled by
physicians [34, 35]. One of the main reasons is the per-
ceived high number of unimportant messages, and the lack
of time [36]. Moreover a recent study has shown that cli-
nicians who overrule high level drug interaction alerts on
QT-prolongation rarely conduct an ECG as a safety mea-
sure [37]. Overruling drug interaction alerts by pharmacists
has also been an issue in several studies [38, 39], but not
specific for drug interactions with risk of QT-prolongation.
Challenges for the future
There is a clinical dilemma between the need for adequate
treatment of mental disorders and the need to minimize the
risk of QT-prolongation/TdP and other adverse effects (e.g.
the controversy about the regulatory approaches to restrict
the use of citalopram [40]). Clinicians should take into
account the risk–benefit ratio of the drug they want to
prescribe [41]. When it is necessary to prescribe a QT-
prolonging drug, safety measures should be taken to follow
up the risk.
In this study, we observed that QT-prolonging drugs are
often combined in psychiatry and adequate safety measures
are not systematically used in clinical practice, despite
available international guidelines [5, 24, 25]. This high-
lights the need for QT-studies conducted in clinical prac-
tice, with attention to the individual risk factors of the
patients (e.g. baseline QT-prolongation, female sex, elec-
trolyte disturbances, history of cardiac arrhythmia or other
cardiovascular disease). The results of these studies com-
bined with Continuing Medical Education efforts can lead
to an increased awareness of the risk of QT-prolongation
and TdP, and initiatives to improve current practice.
Finally, more specific and practical guidelines, that take
into account the individual risk factors of the patient as
well as lab results, are necessary to help healthcare pro-
fessionals in the management of QT-prolongation in a
responsible way. This approach could lead to better tar-
geted alerts by intelligent software combining multiple data
sources, as has been proposed in the literature as an
important measure to enhance the acceptance rates of drug
interaction alerts [36].
Limitations
We performed a cross-sectional analysis of data from 592
patients from 6 psychiatric institutions. Most interactions
occurred with antipsychotics and antidepressants. We
acknowledge the fact that it is difficult to extend our results
to general hospitals or to primary care medicine, in which
QT-prolonging interactions probably involve other medi-
cation classes (e.g. antibiotics, antifungal agents). This
should be the subject of further study.
Secondly, we only checked for pharmacodynamic drug
interactions with risk of QT-prolongation and did not take
into account the pharmacokinetic interactions. Our results
may therefore underestimate the overall prevalence of QT-
prolonging drug interactions.
The results were obtained in 2008. The precautions and
follow-up of QT-prolongation in the involved psychiatric
institutions may have been improved since 2008. More-
over, the prescribing behavior and formularies may also
have changed since 2008. However, we believe that our
message and discussion are still valid.
Finally, we realize that QT-prolongation is an imperfect
biomarker of arrhythmic risk. The concept of repolarization
reserve limits its sensitivity for the identification of drugs with
pro-arrhythmic potential [1, 42]. On the other hand, QT-pro-
longation is still the most used marker of TdP [43]. At the
moment there are no other validated indicators available to
measure the risk of VA and sudden cardiac death in psychiatry.
Conclusion
Drug combinations associated with increased risk of QT-
prolongation are frequently used in psychiatry. The safety
measures that are used to prevent QT-prolongation and
TdP, are very diverse in different hospitals. More QT-
studies in clinical practice are necessary and persistent
efforts should be undertaken to provide caregivers with
clear and practical guidelines on how to use these drugs in
a responsible and safe way.
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